NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance

Ching Feng Chiu, Yi Wen Chang, Kuang Tai Kuo, Yu Shiuan Shen, Chien Ying Liu, Yang Hao Yu, Ching Chia Cheng, Kang Yun Lee, Feng Chi Chen, Min Kung Hsu, Tsang Chih Ku, Jui Ti Ma, Jen Liang Su

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors harboring an activated mutation on EGFR; however, up to 40% of lung cancer patients exhibit acquired resistance to EGFR-TKIs with an unknown mechanism. FOXO3a, a transcription factor of the forkhead family, triggers apoptosis, but the mechanistic details involved in EGFR-TKI resistance and cancer stemness remain largely unclear. Here, we observed that a high level of FOXO3a was correlated with EGFR mutation-independent EGFR-TKI sensitivity, the suppression of cancer stemness, and better progression-free survival in lung cancer patients. The suppression of FOXO3a obviously increased gefitinib resistance and enhanced the stem-like properties of lung cancer cells; consistent overexpression of FOXO3a in gefitinib-resistant lung cancer cells reduced these effects. Moreover, we identified that miR-155 targeted the 3'UTR of FOXO3a and was transcriptionally regulated by NF-?B, leading to repressed FOXO3a expression and increased gefitinib resistance, as well as enhanced cancer stemness of lung cancer in vitro and in vivo. Our findings indicate that FOXO3a is a significant factor in EGFR mutation-independent gefitinib resistance and the stemness of lung cancer, and suggest that targeting the NF- ?B/miR-155/FOXO3a pathway has potential therapeutic value in lung cancer with the acquisition of resistance to EGFR-TKIs.

Original languageEnglish
Pages (from-to)E2526-E2535
JournalProceedings of the National Academy of Sciences of the United States of America
Volume113
Issue number18
DOIs
Publication statusPublished - May 3 2016

Fingerprint

Epidermal Growth Factor Receptor
Lung Neoplasms
Mutation
Forkhead Transcription Factors
gefitinib
Neoplasms
3' Untranslated Regions
Protein-Tyrosine Kinases
Disease-Free Survival
Apoptosis
Survival
Therapeutics

ASJC Scopus subject areas

  • General

Cite this

NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance. / Chiu, Ching Feng; Chang, Yi Wen; Kuo, Kuang Tai; Shen, Yu Shiuan; Liu, Chien Ying; Yu, Yang Hao; Cheng, Ching Chia; Lee, Kang Yun; Chen, Feng Chi; Hsu, Min Kung; Ku, Tsang Chih; Ma, Jui Ti; Su, Jen Liang.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, No. 18, 03.05.2016, p. E2526-E2535.

Research output: Contribution to journalArticle

Chiu, Ching Feng ; Chang, Yi Wen ; Kuo, Kuang Tai ; Shen, Yu Shiuan ; Liu, Chien Ying ; Yu, Yang Hao ; Cheng, Ching Chia ; Lee, Kang Yun ; Chen, Feng Chi ; Hsu, Min Kung ; Ku, Tsang Chih ; Ma, Jui Ti ; Su, Jen Liang. / NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance. In: Proceedings of the National Academy of Sciences of the United States of America. 2016 ; Vol. 113, No. 18. pp. E2526-E2535.
@article{0534e0bfcaf94b56896e1006ede9fee8,
title = "NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance",
abstract = "Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors harboring an activated mutation on EGFR; however, up to 40{\%} of lung cancer patients exhibit acquired resistance to EGFR-TKIs with an unknown mechanism. FOXO3a, a transcription factor of the forkhead family, triggers apoptosis, but the mechanistic details involved in EGFR-TKI resistance and cancer stemness remain largely unclear. Here, we observed that a high level of FOXO3a was correlated with EGFR mutation-independent EGFR-TKI sensitivity, the suppression of cancer stemness, and better progression-free survival in lung cancer patients. The suppression of FOXO3a obviously increased gefitinib resistance and enhanced the stem-like properties of lung cancer cells; consistent overexpression of FOXO3a in gefitinib-resistant lung cancer cells reduced these effects. Moreover, we identified that miR-155 targeted the 3'UTR of FOXO3a and was transcriptionally regulated by NF-?B, leading to repressed FOXO3a expression and increased gefitinib resistance, as well as enhanced cancer stemness of lung cancer in vitro and in vivo. Our findings indicate that FOXO3a is a significant factor in EGFR mutation-independent gefitinib resistance and the stemness of lung cancer, and suggest that targeting the NF- ?B/miR-155/FOXO3a pathway has potential therapeutic value in lung cancer with the acquisition of resistance to EGFR-TKIs.",
author = "Chiu, {Ching Feng} and Chang, {Yi Wen} and Kuo, {Kuang Tai} and Shen, {Yu Shiuan} and Liu, {Chien Ying} and Yu, {Yang Hao} and Cheng, {Ching Chia} and Lee, {Kang Yun} and Chen, {Feng Chi} and Hsu, {Min Kung} and Ku, {Tsang Chih} and Ma, {Jui Ti} and Su, {Jen Liang}",
year = "2016",
month = "5",
day = "3",
doi = "10.1073/pnas.1522612113",
language = "English",
volume = "113",
pages = "E2526--E2535",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
publisher = "National Academy of Sciences",
number = "18",

}

TY - JOUR

T1 - NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance

AU - Chiu, Ching Feng

AU - Chang, Yi Wen

AU - Kuo, Kuang Tai

AU - Shen, Yu Shiuan

AU - Liu, Chien Ying

AU - Yu, Yang Hao

AU - Cheng, Ching Chia

AU - Lee, Kang Yun

AU - Chen, Feng Chi

AU - Hsu, Min Kung

AU - Ku, Tsang Chih

AU - Ma, Jui Ti

AU - Su, Jen Liang

PY - 2016/5/3

Y1 - 2016/5/3

N2 - Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors harboring an activated mutation on EGFR; however, up to 40% of lung cancer patients exhibit acquired resistance to EGFR-TKIs with an unknown mechanism. FOXO3a, a transcription factor of the forkhead family, triggers apoptosis, but the mechanistic details involved in EGFR-TKI resistance and cancer stemness remain largely unclear. Here, we observed that a high level of FOXO3a was correlated with EGFR mutation-independent EGFR-TKI sensitivity, the suppression of cancer stemness, and better progression-free survival in lung cancer patients. The suppression of FOXO3a obviously increased gefitinib resistance and enhanced the stem-like properties of lung cancer cells; consistent overexpression of FOXO3a in gefitinib-resistant lung cancer cells reduced these effects. Moreover, we identified that miR-155 targeted the 3'UTR of FOXO3a and was transcriptionally regulated by NF-?B, leading to repressed FOXO3a expression and increased gefitinib resistance, as well as enhanced cancer stemness of lung cancer in vitro and in vivo. Our findings indicate that FOXO3a is a significant factor in EGFR mutation-independent gefitinib resistance and the stemness of lung cancer, and suggest that targeting the NF- ?B/miR-155/FOXO3a pathway has potential therapeutic value in lung cancer with the acquisition of resistance to EGFR-TKIs.

AB - Therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs, such as gefitinib or erlotinib) significantly prolongs survival time for patients with tumors harboring an activated mutation on EGFR; however, up to 40% of lung cancer patients exhibit acquired resistance to EGFR-TKIs with an unknown mechanism. FOXO3a, a transcription factor of the forkhead family, triggers apoptosis, but the mechanistic details involved in EGFR-TKI resistance and cancer stemness remain largely unclear. Here, we observed that a high level of FOXO3a was correlated with EGFR mutation-independent EGFR-TKI sensitivity, the suppression of cancer stemness, and better progression-free survival in lung cancer patients. The suppression of FOXO3a obviously increased gefitinib resistance and enhanced the stem-like properties of lung cancer cells; consistent overexpression of FOXO3a in gefitinib-resistant lung cancer cells reduced these effects. Moreover, we identified that miR-155 targeted the 3'UTR of FOXO3a and was transcriptionally regulated by NF-?B, leading to repressed FOXO3a expression and increased gefitinib resistance, as well as enhanced cancer stemness of lung cancer in vitro and in vivo. Our findings indicate that FOXO3a is a significant factor in EGFR mutation-independent gefitinib resistance and the stemness of lung cancer, and suggest that targeting the NF- ?B/miR-155/FOXO3a pathway has potential therapeutic value in lung cancer with the acquisition of resistance to EGFR-TKIs.

UR - http://www.scopus.com/inward/record.url?scp=84970984338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84970984338&partnerID=8YFLogxK

U2 - 10.1073/pnas.1522612113

DO - 10.1073/pnas.1522612113

M3 - Article

C2 - 27091996

AN - SCOPUS:84970984338

VL - 113

SP - E2526-E2535

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 18

ER -